Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Septerna, Inc.NASDAQ: SEPN
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q3 FY2026 stock-based compensation of $5.92M rose 133.9% year over year, behind the +177.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 16.7% from the prior quarter. Over 3 fiscal years it compounded at +77.3% a year.
Context
- Stock-based compensation amounted to 18.4% of revenue in FY2025, down 274.8 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +133.9% toward the trailing-twelve-month pace of +177.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 8.48M USD
- Year-over-year change
- +168.9%
- 3-year CAGR
- +77.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.48M | +168.9% |
| FY2024 | 2024-12-31 | 3.15M | +94.6% |
| FY2023 | 2023-12-31 | 1.62M | +6.6% |
| FY2022 | 2022-12-31 | 1.52M | — |
Stock-Based Compensation vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's LTM Sep 2026 stock-based compensation of $19.67M is the 4th largest of the 7 companies compared; the peer median is $15.61M.
- Its year-over-year change of +177.6% is the 2nd highest of 6, against a peer median of +92.0%.
- Stock-based compensation amounts to 20.4% of revenue for SEPN, versus a peer median of 53.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $51.48M | +103.6% | +125.9% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $41.75M | +456.0% | +204.9% | — |
| LTM Mar 2026 | $20.28M | +92.0% | +34.5% | 101.4% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $19.67M | +177.6% | +77.3% | 20.4% |
KLRAKailera Therapeutics, Inc. | FY2025 | $10.94M | — | — | — |
| LTM Mar 2026 | $4.16M | -75.9% | -2.7% | — | |
| LTM Mar 2026 | $1.96M | -41.6% | — | 5.3% | |
| Peer median (excluding SEPN) | $15.61M | +92.0% | +80.2% | 53.4% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (27.68M) | 4.18M | (71.8M) | (48.88M) |
| Depreciation & Amortization | 577K | 848K | 1.4M | 1.6M |
| Deferred Income Tax | 0 | 491K | (491K) | 0 |
| Stock-Based Compensation | 1.52M | 1.62M | 3.15M | 8.48M |
| Change in Working Capital | 1.75M | 926K | 248K | 162.78M |
| Accounts Receivables | 0 | (151K) | (20K) | (10.19M) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.73M | (653K) | 723K | 6.6M |
| Other Working Capital | 20K | 1.73M | (455K) | 166.36M |
| Other Non-Cash Items | 530K | (46.79M) | 18K | (13.79M) |
| Operating Cash Flow | (23.3M) | (38.72M) | (67.47M) | 110.19M |
| Capital Expenditures | (1.29M) | (2.88M) | (2.1M) | (518K) |
| Acquisitions (Net) | 0 | 0 | 0 | 12.5M |
| Purchases of Investments | 0 | 0 | (213.39M) | (450.95M) |
| Sales of Investments | 0 | 0 | 32.27M | 209.62M |
| Other Investing Activities | 0 | 25M | 22.63M | 0 |
| Investing Cash Flow | (1.29M) | 22.12M | (160.6M) | (229.35M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 82K | 0 | 302.79M | 1.69M |
| Common Stock Repurchased | 0 | (1K) | (1K) | (1K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 52K | 0 |
| Financing Cash Flow | 30.05M | 74.52M | 377.78M | 1.69M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.46M | 57.92M | 149.71M | (117.47M) |
| Free Cash Flow | (24.59M) | (41.6M) | (69.57M) | 109.67M |
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.